Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Common Equity (2016 - 2025)

Marimed has reported Common Equity over the past 15 years, most recently at $50.0 million for Q4 2025.

  • Quarterly Common Equity fell 14.58% to $50.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.0 million through Dec 2025, down 14.58% year-over-year, with the annual reading at $50.0 million for FY2025, 14.58% down from the prior year.
  • Common Equity was $50.0 million for Q4 2025 at Marimed, down from $54.3 million in the prior quarter.
  • Over five years, Common Equity peaked at $80.9 million in Q2 2023 and troughed at $14.7 million in Q1 2021.
  • The 5-year median for Common Equity is $57.1 million (2022), against an average of $54.3 million.
  • Year-over-year, Common Equity surged 41994.93% in 2021 and then fell 19.93% in 2025.
  • A 5-year view of Common Equity shows it stood at $36.3 million in 2021, then soared by 57.88% to $57.3 million in 2022, then grew by 20.2% to $68.9 million in 2023, then fell by 15.01% to $58.5 million in 2024, then dropped by 14.58% to $50.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Common Equity are $50.0 million (Q4 2025), $54.3 million (Q3 2025), and $56.9 million (Q2 2025).